Sio Gene Therapies Inc.
Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$71.6M | −$32.6M | −$72.2M | −$128.9M | −$220.7M | −$182.0M |
| Net income | −$71.9M | −$32.4M | −$8.6M | −$28.1M | −$51.9M | −$69.3M |
| Total assets | $75.1M | $135.1M | $93.7M | $122.7M | $160.8M | $222.5M |
| Total liabilities | $14.7M | $11.8M | $32.1M | $66.5M | $89.5M | $97.7M |
| Equity | $60.3M | $123.4M | $61.6M | $56.2M | $71.3M | $124.8M |
| EPS (diluted) | $-0.98 | $-0.62 | $-0.20 | — | — | — |
| Shares out. | 73.7M | 69.6M | 40.3M | 22.8M | 107.8M | 107.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- −119.1%
- Return on assets
- −95.7%
- Return on capital (ROCE)
- −115.4%
- Liabilities / assets
- 19.6%
- Debt / equity
- 0.24×
- Book value / share
- $0.82
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -34.45distress
- Accruals / assets
- −15.4%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Nassif David W.Officer — Chief Financial Officer | Dec 8, 2021 | Grant | 17,534 | $0.00 |
| Cheruvu PavanOfficer — Chief Executive Officer | Dec 8, 2021 | Grant | 37,567 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Director / officer change · Shareholder voteApr 6, 2023
- Delisting / listing-standard noticeMar 15, 2023
- Results of operationsFeb 14, 2023
- Other material eventDec 14, 2022
- Results of operationsNov 10, 2022
- Delisting / listing-standard noticeSep 14, 2022
- Results of operationsAug 11, 2022
- Results of operationsJun 14, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.